Back to search

Ireland· IE-PA-PA0126/394/008

Selexipag Clonmel 1600 microgram film-coated tablets

A selexipag product containing selexipag, registered in Ireland by Clonmel Healthcare Ltd. The same ATC class is registered in 13 of our 19 countries.

ATC B01AC27

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedSelexipag Clonmel 1600 microgram film…ATCB01AC27REGISTER NO.IE-PA-PA0126/394/008PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Selexipag is registered in 13 of 19 countries.

Countries holding a registration under ATC B01AC27 (selexipag), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 8 of them publish a price we can compare per daily dose

Selexipag · ATC B01AC27

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of selexipag costs, country by country.

Normalised to the WHO defined daily dose (1.8 mg), the median price runs from $809.99 in Switzerland to $1232.99 in Italy — a ×1.5 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Selexipag · price per daily dose (1.8 mg)

USD · FX 28 Sept 2026

  • IT Italy$1232.99
  • CH Switzerland$809.99
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

HPRA (Ireland)
Active substance
Selexipag
Manufacturer
Clonmel Healthcare Ltd
Country
Ireland (IE)
ATC code
B01AC27
ATC class
Selexipag
Defined daily dose
1.8 mg, O
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    PA0126/394/008

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

237 interactions on record for selexipag.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Selexipag · interactions on record

237 records

  • 1 severe
  • 232 moderate
  • 4 minor

Most severe, free to view

  • GemfibrozilC10AB04severe
  • PapaverineA03AD01moderate
  • MannitolA06AD16moderate
  • GlycerolA06AX01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Selexipag in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All selexipag products

Authorised across Europe · EMA

The same active substance is authorised in 18 EEA countries. Names it is sold under:

  • Austria · Selexipag Ratiopharm
  • Cyprus · Selexipag Accord
  • Denmark · Selexipag Accord, Selexipag Stada
  • Estonia · Selexipag Stada
  • Spain · Selexipag Accord, Selexipag Stada
  • Greece · Xipeno
  • Croatia · Seleksipag Accord
  • Iceland · Selexipag Stada, Uptravi
  • Italy · Selexipag Accord, Selexipag Eg
  • Liechtenstein · Uptravi
  • Lithuania · Selexipag Stada
  • Latvia · Selexipag Stada
  • Malta · Selexipag Clonmel
  • Netherlands · Seleksipag Accord, Selexipag Abdi
  • Norway · Selexipag Accord, Selexipag Stada
  • Poland · Selexipag, Selexipag Accord
  • Portugal · Selexipag Accord, Selexipag Teva
  • Sweden · Selexipag, Selexipag Accord

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9991cef2-30e5-46b6-af67-6d96f485dc58
GET /v1/drugs/9991cef2-30e5-46b6-af67-6d96f485dc58?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "routes": [
    "Oral use"
  ],
  "source": "hpra",
  "atc_all": [
    "B01AC27"
  ],
  "strength": null,
  "pa_number": "PA0126/394/008",
  "substances": [
    "Selexipag"
  ],
  "legal_basis": "Generic application (Article 10(1) of Directive No 2001/83/EC)",
  "market_info": "Not marketed",
  "authorised_at": "03/10/2025",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about selexipag.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.